BACKGROUND: Activation of T cells requires both the interaction of T-cell receptor with major histocompatibility complex on the antigen-presenting cell and costimulatory signals, for instance the B7 antigens expressed on antigen-presenting cells and the CD28 molecule expressed on T cells. A recombinant fusion protein, CTLA4-Ig, has been produced that contains the extracellular domain of human CTLA4 fused to IgG1 constant region and that binds the B7 molecule with high affinity. Blocking the CD28/B7 interaction with CTLA4-Ig inhibits T cell activation in vitro and in vivo. METHODS: We used CTLA4-Ig in a fully MHC-mismatched mouse keratoplasty model. The animals were divided into four groups: (1) no treatment, (2) intraperitoneal treatment with 130 micrograms CTLA4-Ig, (3) intraperitoneal treatment with 300 micrograms CTLA4-Ig, (4) subconjunctival treatment with 290 micrograms CTLA4-Ig. RESULTS: The allograft reaction occurred in untreated animals between days 12 and 16 (mean 13.5). While topical application of CTLA4-Ig seemed to shorten the graft survival (mean 11.6 days) and systemic application of 130 micrograms had no influence (mean 14.0), only intraperitoneal injection of 300 micrograms of CTLA4-Ig prolonged the survival of allografts (mean > 20 days) (P < 0.01). CONCLUSION: CTLA4-Ig prolonged significantly the survival of corneal allografts in a fully MHC-mismatched mouse keratoplasty model, but the small antigen load of the corneal transplant and the anterior chamber-associated immune deviation (ACAID) may have a disadvantage to induce tolerance in this model of CTLA4-Ig therapy.
BACKGROUND: Activation of T cells requires both the interaction of T-cell receptor with major histocompatibility complex on the antigen-presenting cell and costimulatory signals, for instance the B7 antigens expressed on antigen-presenting cells and the CD28 molecule expressed on T cells. A recombinant fusion protein, CTLA4-Ig, has been produced that contains the extracellular domain of humanCTLA4 fused to IgG1 constant region and that binds the B7 molecule with high affinity. Blocking the CD28/B7 interaction with CTLA4-Ig inhibits T cell activation in vitro and in vivo. METHODS: We used CTLA4-Ig in a fully MHC-mismatched mouse keratoplasty model. The animals were divided into four groups: (1) no treatment, (2) intraperitoneal treatment with 130 micrograms CTLA4-Ig, (3) intraperitoneal treatment with 300 micrograms CTLA4-Ig, (4) subconjunctival treatment with 290 micrograms CTLA4-Ig. RESULTS: The allograft reaction occurred in untreated animals between days 12 and 16 (mean 13.5). While topical application of CTLA4-Ig seemed to shorten the graft survival (mean 11.6 days) and systemic application of 130 micrograms had no influence (mean 14.0), only intraperitoneal injection of 300 micrograms of CTLA4-Ig prolonged the survival of allografts (mean > 20 days) (P < 0.01). CONCLUSION:CTLA4-Ig prolonged significantly the survival of corneal allografts in a fully MHC-mismatched mouse keratoplasty model, but the small antigen load of the corneal transplant and the anterior chamber-associated immune deviation (ACAID) may have a disadvantage to induce tolerance in this model of CTLA4-Ig therapy.
Authors: M E Russell; W W Hancock; E Akalin; A F Wallace; T Glysing-Jensen; T A Willett; M H Sayegh Journal: J Clin Invest Date: 1996-02-01 Impact factor: 14.808
Authors: P S Linsley; P M Wallace; J Johnson; M G Gibson; J L Greene; J A Ledbetter; C Singh; M A Tepper Journal: Science Date: 1992-08-07 Impact factor: 47.728
Authors: U Kunzendorf; T Pohl; S Bulfone-Paus; H Krause; M Notter; A Onu; G Walz; T Diamantstein Journal: J Clin Invest Date: 1996-03-01 Impact factor: 14.808
Authors: G J Freeman; F Borriello; R J Hodes; H Reiser; J G Gribben; J W Ng; J Kim; J M Goldberg; K Hathcock; G Laszlo Journal: J Exp Med Date: 1993-12-01 Impact factor: 14.307
Authors: Tatsuhiko Asai; Beom K Choi; Patrick M Kwon; Won Y Kim; Jung D Kim; Dass S Vinay; Bryan M Gebhardt; Byoung S Kwon Journal: Immunology Date: 2007-03-22 Impact factor: 7.397
Authors: Justyna Sakowska; Paulina Glasner; Maciej Zieliński; Piotr Trzonkowski; Leopold Glasner Journal: J Immunol Res Date: 2021-10-03 Impact factor: 4.818